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O-GlcNAc hydrolase, OGA, removes O-linked N-acetylglucosamine (O-GlcNAc) from myriad 12 
nucleocytoplasmic proteins. Through co-expression and assembly of OGA fragments we 13 
determined the 3-D structure of human OGA, revealing an unusual helix exchanged dimer 14 
that lays a structural foundation for an improved understanding of substrate recognition 15 
and regulation of OGA. Structures of OGA in complex with a series of inhibitors define a 16 
precise blueprint for the design of inhibitors having clinical value. 17 
 18 
The dynamic O-GlcNAc modification of hundreds of nuclear and cytoplasmic proteins plays 19 
diverse roles in a range of cellular processes including, for example, transcriptional 20 
regulation and stress response (reviewed in Ref1,2). Dysregulation of O-GlcNAcylation has 21 
been implicated in diseases including cancer3, obesity4, and neurodegenerative diseases.5,6 22 
Notably, therapeutic agents targeting the O-GlcNAc modification have entered phase I 23 
clinical trials, stimulating interest in the molecular and chemical basis of O-GlcNAcylation 24 
and its manipulation with small molecules.7 25 
Within mammals, this modification of serine and threonine residues is installed by O-GlcNAc 26 
transferase, OGT, for which extensive structural data are available.8,9 The O-GlcNAc 27 
modification is removed by O-GlcNAc hydrolase, OGA.10 Structures of bacterial homologs of 28 
OGA from CAZY family GH8411 (originally, and most notably Bacteroides thetaiotaomicron 29 
(BtGH84)12 and Clostridium perfringens (CpNGA )13), having a conserved active site with OGA, 30 
have aided glycomimetic inhibitor design. Indeed, compounds based on the neighboring-31 
group catalytic mechanism12,14 have been applied in cellular and animal studies. The absence 32 
of structural data for mammalian OGA, however, has limited efforts toward inhibitor design 33 
and curtailed insight into peptide substrate binding and association with binding partners. 34 
Accordingly, as part of our long-standing effort to understand O-GlcNAcase, we set out to 35 
dissect human OGA (hOGA) and study its structure as well as its binding to different inhibitor 36 
classes.  37 
We first sought to establish a functional construct of human OGA for structural analyses. 38 
hOGA is a complex multi-domain protein, produced as two splice variants; long-form OGA-L 39 
and a less-active short form, OGA-S (reviewed in ref 15). OGA-L consists of an N-terminal 40 
catalytic domain (GH84), a helical domain, extensive regions predicted as disordered, and a 41 
C-terminal domain of unknown function having similarity to histone acetyl transferase (HAT) 42 
domains (Supplementary Results, Supplementary Fig. 1a). We generated various truncated 43 
constructs and screened possible domain boundaries15, none of these (Supplementary Table 44 
1), however, yielded protein amenable to structural analysis.  45 
Central to our successful strategy was that hOGA can be cleaved by caspase-3 into two 46 
fragments, which remain tightly associated and active in solution.16 Accordingly, co-47 
expression of two hOGA fragments should permit their systematic truncation and removal of 48 
putative disordered regions, yet allow their assembly into active hOGA in a form suitable for 49 
crystallization. We co-expressed an extensive series of N- and C-terminal constructs in which 50 
the putative disordered regions were systematically truncated (Supplementary Table 1). 51 
Constructs were screened for formation of stable complexes and screened for crystallization. 52 
Ultimately, a construct comprising amino acids 11-396 (N-terminal fragment) and 535-715 53 
(C-terminal fragment) (Supplementary Fig. 1b) yielded crystals suitable for structure 54 
determination. Furthermore, this construct, which we term "Split1", has essentially wild-55 
type catalytic activity toward synthetic substrates (Fig. 1a) and processes O-GlcNAcylated 56 
proteins (Fig. 1b, Supplementary Fig. 2, 3).  57 
We solved the structure of Split1 (Supplementary Table 2) by molecular replacement using a 58 
sculpted model of BtGH84 having 31% identity in the catalytic domain. This initial model was 59 
greatly improved by extensive rebuilding, guided by the positions of sulfur atoms from 60 
methionine and cysteine residues, observed using a long wavelength dataset, 61 
(Supplementary Fig. 4). The final model of Split1 (11-396 / 535-715; in which residues 11-58, 62 
341-370, 535-536, 596-598, 674-675 and 696-706 are disordered) reveals a two-domain 63 
structure, with an N-terminal catalytic domain followed by a C-terminal helical bundle (Fig. 64 
1c). hOGA forms a dimer with a contact interface of 4390 Å2, calculated using PISA.17  We 65 
confirmed that the dimer also forms in solution by size exclusion chromatography with 66 
multi-angle light scattering (SEC-MALS) (Supplementary Fig. 5a). Notably, a dimer swap of 67 
the C-terminal helix from each of the helical domains (Q676-P694) completes the open 3-68 
helix bundle to yield a closed 4-helix coiled coil bundle (Fig. 1c). This swap is essential for 69 
stable interactions between both the two domains and the two monomers. Deletion of this 70 
helix compromised dimer formation as assessed by SEC-MALS, and led to disassembly into 71 
its peptide components to yield a near inactive construct (Fig. 1a, Supplementary Fig. 5b, 6). 72 
SEC-MALS also showed near full-length hOGA (His(6)9-916) is primarily a dimer 73 
(Supplementary Fig. 5c). Previous evidence on the native multimerization status of hOGA 74 
was conflicting and depended on the method used.10,18,19 When superposed with the 75 
bacterial homolog structures, BtGH8412, CpNGA13 and Oceanicola granulosus OGA 76 
(OgOGA)20 there is structural conservation of the catalytic domain and in particular the о1 77 
sugar binding subsite that we define as the active site pocket (Supplementary Fig. 7). The 78 
majority of active site residues comprising this subsite are conserved and mutations of these 79 
residues in these enzymes BtGH8412,13,20 and in hOGA21, coupled with detailed mechanistic 80 
studies, 14,21,22 provide clear support for a catalytic mechanism involving substrate-assisted 81 
catalysis from the substrate acetamido group. The helical regions that contribute to the 82 
putative peptide-binding cleft (see below) are, however, markedly different; both in 83 
organization and residue identity (Supplementary Fig. 7-9). The most similar helical domain 84 
is seen for OgOGA20, though that model was assigned a monomeric organization lacking the 85 
helix exchange observed in hOGA.  86 
The active site pocket of hOGA is located at the base of a V-shaped cleft (~ 22 x 25 Å with an 87 
angle of ~ 70°) formed between the catalytic domain of monomer 1 and the C-terminal 88 
helical bundle of the other monomer of the dimer (Fig. 1c, Supplementary Fig. 10). The 89 
unusual dimer topology thus plays an unforeseen functional as well as structural  role by 90 
contributing to formation of this groove, which likely binds the peptide component of 91 
substrates. The helical bundle contributes a rigid structure (Supplementary Fig. 10), but also 92 
a flexible loop connecting the swapped helix, which can adopt different conformations as 93 
discussed below. This mobility may confer plasticity to this groove, perhaps allowing it to 94 
accommodate different substrates and inhibitors. Notably, our analysis revealed unexpected 95 
density in this groove (Fig. 1d, Supplementary Fig. 11a) that we assigned as the C-terminal 96 
end (P707-Y715) of the helical bundle with Y715 adopting a position that is consistent with 97 
the position of an O-GlcNAcylated serine/threonine residue (Supplementary Fig. 12). 98 
Notably, this crystal-packing derived peptide runs in the opposite direction to that observed 99 
in bacterial structures20 and thus is only indicative of the peptide binding surface; further 100 
study of peptide complexes will be needed to clarify binding of protein substrates.  101 
Key to our analysis of hOGA is how it binds inhibitors. Extensive soaking of diverse chemical 102 
inhibitors was performed to displace the C-terminal peptide. Structures of complexes with 103 
the mechanism-derived inhibitor Thiamet-G (Ki=0.9 nM),
23 the PUGNAc-imidazole hybrid 104 
(Ki=3.9 µM)24 and a potent derivative (VV347) of recently described pyrrolidine inhibitors 105 
(Ki=8 nM),
25 were determined (Fig. 2, Supplementary Fig. 11b, 13, Supplementary Note). 106 
The sugar-like moieties of these inhibitors occupy the о1 GlcNAc binding site, making 107 
hydrogen bonds with, for example G67, K98, N280, D285 and N313. The alkyl amino-group 108 
of Thiamet-G fills the pocket, formed by C215, Y219 and W278. In all three cases the 109 
catalytic residues D174 and D175 are engaged with the inhibitors, representing a closed 110 
conformation. D174 interacts with both nitrogens of the N-aminothiazoline moiety as 111 
expected for this transition state mimic. The acetamido groups of VV347, and PUGNAc-112 
imidazole, point into the same pocket with the acetamido nitrogen interacting with D174 113 
(Fig. 2, Supplementary Fig. 14), consistent with its role as polarizing residue. D175 points 114 
towards the anomeric carbon as expected for its role as general acid/base in the catalytic 115 
cycle.22 Interactions of the sugar-like moiety of these inhibitors within the о1 sugar binding 116 
subsite are conserved between hOGA and their bacterial counterparts, explaining the 117 
success of inhibitors targeting this site. Not conserved, however, are residues outside the -1 118 
sugar binding subsite. These residues participate in the recognition of the aglycon 119 
component of inhibitors that project out of the active site pocket and can be observed here 120 
for the first time (Fig. 2, Supplementary Fig. 11b).  121 
The aglycon of the glucoimidazole inhibitor mainly interacts with residues of the catalytic 122 
domain that are outside the -1 binding site pocket, notably F223 and V254. The phenyl group 123 
is within 4.5 Å of the loop comprising residues 677-683 of the helical bundle of monomer 2 124 
(680-loop) suggesting a direct contribution of the helical bundle domain to the binding of the 125 
inhibitor and potential substrates. The complex with VV347 (Fig. 2) reveals interactions with 126 
multiple residues of the helical bundle domain. The helix comprising residues 633-662 and 127 
the 680-loop, are core structural elements of the peptide-binding groove. The 128 
trifluoromethyl-phenyl group of VV347 binds in a pocket formed by the side chain of W645, 129 
part of helix ɲ4 and W679, part of the 680-loop, which undergoes a major reorientation 130 
(Supplementary Fig. 15). Previous mutagenesis studies suggest the 680-loop  interacts with 131 
protein substrates20 though further study will illuminate the precise roles of this feature. 132 
In summary, we report a functional construct of human OGA obtained by exploiting the abil-133 
ity of the N- and C-terminal fragments of hOGA to associate stably. The structure revealed an 134 
unusual obligate dimer with intertwined helical bundle domains that leads to residues from 135 
both domains contributing to formation of the substrate-binding site. Structures of OGA in 136 
complex with rationally-designed high affinity inhibitors define both the active site pocket 137 
and, crucially, the surrounding peptide-binding and aglycon regions in a manner that is 138 
unique to mammalian OGA. Strikingly, part of this peptide binding site is a flexible loop con-139 
necting the swapped helix of the helical bundle domain with the opposite peptide binding 140 
groove, which may open-up possible communication between active sites in response to 141 
peptide binding. Exploitation of this peptide binding groove will offer new opportunities for 142 
the design of OGA inhibitors as research tools and for potential clinical use in treating O-143 
GlcNAc related diseases. 144 
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Figure legends: 227 
Figure 1: Function and structure of hOGA. a) Michaelis-Menten kinetics of crystallized construct Split 1, full-228 
length hOGA (OGA-L) and Split 2. The kinetic parameters for the OGA variants are, OGA-L: Vmax = 1.10 ± 0.02ʅM 229 
min-1; KM = 92.47 ± 4.86µM, and OGA-Split 1: Vmax = 1.11 ± 0.03ʅM min-1; KM = 40.93 ± 3.30µM. Therefore, the 230 
catalytic efficiency (kcat/KM) of OGA-L is roughly similar (2.3 fold lower) to OGA-Split 1 when using pNP-GlcNAc 231 
as the substrate. Data represent average of quadruplicate rate measurements ± s. d. b) Immunoblot analysis 232 
showing that Split1 can digest recombinant O-GlcNAcylated TAB1, evaluated using anti-O-GlcNAc antibody 233 
CTD110.6 anti-Histidine antibody as a loading control. Thiamet-G inhibits digestion. c) Ribbon diagram of the 234 
hOGA dimer, colored by chain. The helix (Q676-P694) swapped between the two helical bundles is marked with 235 
a star. The position of the active site (-1 sugar binding site) is indicated by the Van der Waals' surface of the 236 
inhibitor Thiamet-G in bluegreen. d) Binding of the C-terminal peptide (shown with its Van der Waals surface in 237 
bluegreen) of the helical bundle fragment to the hOGA peptide-binding groove. Full blots are provided in the 238 
Supplementary Fig. 15. 239 
Figure 2: Ligand binding to hOGA. a) Binding of Thiamet-G (left), the PUGNAc-imidazole hybrid (middle) and 240 
the pyrrolidine derivative VV347 in the active site of hOGA. The corresponding electron density is shown at 241 
2.0 ʍ r.m.s.d. (0.28 e/Å3) for Thiamet-G. For the PUGNAc-imidazole hybrid (middle) at 1.5 ʍ r.m.s.d. (0.17 242 
e/Å3), and the pyrrolidine derivative VV347 at 1.5 ʍ r.m.s.d. (0.21 e/Å3). The catalytic residues as well the 243 
acetamido pocket forming residues are shown as sticks. c) Van der Waals' surface of the inhibitor binding sites 244 
showing that the -1-subsite is deeply buried with the aglycon units extending outwards interacting with both 245 
domains of hOGA.  246 
Online Methods: 247 
Cloning, expression and purification 248 
The gene of the longest isoform of hOGA (hOGA-L (Uniprot Accession number: O60502)) was 249 
synthesized in a codon optimized form for recombinant expression in Escherichia coli. The successful 250 
expression construct encoded the N-terminal region of hOGA, comprising amino acids 11-396, and 251 
the C-terminal region, comprising amino acids 535-715. The N-terminal construct was cloned in the 252 
vector pACYC-Duet (Millipore) using the sequence and ligation independent cloning method 26 in 253 
frame with an N-terminal His6-Tag. The C-terminal construct was cloned into the vector pET-YSBLIC3C 254 
27 with an N-terminal His6-Tag followed by a 3C-protease cleavage site using the same method. The 255 
nucleotide sequences of all made constructs were confirmed by sequencing. Both vectors were 256 
simultaneously transformed into E. coli Bl21(DE3)-Gold (Agilent) for subsequent protein expression. 257 
Cells were grown in 2L TB-medium to an OD600 of ~ 1.0 and protein synthesis was then induced by 258 
adding IPTG to a final concentration of 0.1 mM. Protein expression was carried out at 16 °C with an 259 
induction time of 20 h. The cells were harvested by centrifugation at 4500xg for 20 min, flash frozen 260 
and stored at -20°C until required.  261 
For purification of the hOGA complex, cells were resuspended in 50 mM HEPES pH 7.0, 750 mM NaCl, 262 
20 mM imidazole, and 0.5 mM DTT (resuspension buffer). Cells were lysed using a French Press at 25 263 
kPsi. The lysate was cleared by centrifugation at 50,000 g for 1h and the supernatant was passed 264 
through a 10 mL HisTrap FF column (GE Healthcare) pre-equilibrated with resuspension buffer. The 265 
bound hOGA was purified by gradient elution over 10 column volumes using 0 to 50% of elution 266 
buffer (50 mM HEPES pH 7.0, 750 mM NaCl, 500 mM imidazole and 0.5 mM DTT).  hOGA containing 267 
fractions were combined, concentrated by ultrafiltration using Vivaspin columns (Sartorius) with a 268 
molecular weight cut-off (MWCO) of 30 kDa, and applied to a Superdex S200 column (GE Healthcare) 269 
pre-equilibrated with size-exclusion buffer (10 mM HEPES pH 7.0, 250 mM NaCl, 1 mM DTT).  270 
Fractions corresponding to the dimeric form of hOGA were combined and concentrated to 20 mg/ml 271 
by ultrafiltration with a Vivaspin (MWCO: 30 kDa) column, flash frozen using liquid nitrogen, and 272 
stored at -80°C until required.   273 
Crystallization and data collection 274 
Initial crystallization conditions were identified using commercially available screens from Hampton 275 
and Molecular Dimension in a 96 well sitting drop screening format. Further optimization in a 48 well 276 
sitting drop format provided suitable conditions for reliable crystallization (crystallization solution: 277 
0.1-0.2 M (NH4)3-citrate pH 6.5-7.5; 16-24 % PEG 3350). Optimal crystals were reliably obtained by 278 
micro seeding with previously obtained crystals. For data collection, protein crystals were transferred 279 
into crystallization solution containing 25% PEG3350 (cryoprotectant solution), which enabled 280 
cryoprotection of the crystals. Crystals were recovered using a Nylon microfibre loop (Hampton) and 281 
flash frozen in liquid nitrogen.  For soaking experiments the inhibitors were dissolved in 10 % (v/v) 282 
DMSO to a concentration of 100 mM and added to a drop containing the cryoprotectant solution to a 283 
final inhibitor concentration of 10 mM. Crystals were soaked with inhibitors for times ranging from 284 
48 hours to 1 week. The resulting crystals were handled as described above. Data were collected at 285 
the Diamond light source beamlines I02, I03 or I04 using a Pilatus 6M detector (Dectris) at a 286 
wavelength of 0.979 Å. Data were collected over 180° with an oscillation angle of 0.1°.  Data were 287 
integrated with XDS 28, integrated in the XIA2  pipeline 29 and scaled using AIMLESS 30. 288 
Structure solution and refinement 289 
The structure was solved by molecular replacement using Phaser31 in conjunction with a sculpted 290 
model of BtGH84 (PDB-ID 2CHO)12. The initial model was rebuilt and refined using Buccaneer 32. The 291 
final model was obtained by alternating rounds of manual model building in COOT33, followed by 292 
reciprocal refinement with Refmac34 or Phenix35. For inhibitor complexes the apo-structure was 293 
refined against data from a crystal soaked with the respective inhibitor. If clear density for a bound 294 
inhibitor could be identified a model of the ligand was built using Acedrg, part of the CCP4- software 295 
package36 and incorporated in the apo model which was then subsequently refined. The quality of 296 
the final models were judged using MolProbity 37. The number of outliers is between 0.2 to 0.4 %.  297 
Figures of the structural models were prepared using CCP4MG 38.  298 
Enzyme kinetics 299 
Initial rate experiments of OGA-L, OGA-Split 1, and OGA-Split 2 catalyzed pNP-GlcNAc hydrolysis were 300 
carried out in PBS buffer (pH 7.4) and monitored continuously at 25°C at a wavelength of 405 nm 301 
using a SpectraMax i3x multi-mode plate reader from Molecular Devices. Reactions were performed 302 
in a 384 well clear assay plate from Corning (Product #3702) in a final reaction volume of 45 µl. 303 
Steady state kinetic values were attained from substrate dose response curves using 50 nM of the 304 
OGA-L, OGA-Split 1, and OGA-Split 2 variants unless otherwise stated and varying concentrations of 305 
pNP-GlcNAc. Reaction velocities were determined by linear regression of the progress curves over a 306 
15 min period.  The amount of product formed was assessed by creating a pNP standard curve in PBS 307 
buffer. The substrate dose-response curves were then fit to the Michaelis-Menten equation using the 308 
GraphPad Prism5 software package.  309 
 310 
Inhibition assays were performed using a final concentration of 20 nM OGA-L and 200 ʅM of 4-311 
methylumbelliferyl-2-acetamido-2-deoxy-ɴ-D-glucopyranoside with various concentrations of VV-347 312 
and Thiamet-G. The assay was performed at 37°C in a final volume of 45µl in inhibition buffer: PBS 313 
pH7.4, 0.0025% BSA, 0.0025mM DTT. Reactions were initiated with the addition of enzyme, and re-314 
action progress was monitored continuously (excitation and emission wavelengths: 350, and 445nm) 315 
over a 10-minute period. The amount of fluorophore liberated was assessed using a standard curve 316 
for 4-methylumbelliferone in inhibition buffer. Inhibitor Ki values were determined using the Morri-317 
son equation for tight binding inhibition as described previously 39. All curve fitting for enzyme kinet-318 
ics and inhibition experiments was performed using GraphPad Prism, and error bars correspond to 319 
S.D. from three technical replicates (triplicate reads). The experiments were all repeated at least 320 
twice to ensure reproducibility of the data. 321 
 322 
SEC-MALS 323 
 324 
Experiments were conducted on a system comprising a Wyatt HELEOS-II multi-angle light 325 
scattering detector and a Wyatt rEX refractive index detector linked to a Shimadzu HPLC system 326 
(SPD-20A UV detector, LC20-AD isocratic pump system, DGU-20A3 degasser and SIL-20A 327 
autosampler). Work was conducted at room temperature (20 ±2°C). Sample injection volume was 328 
100 µL at a protein concentration of 5 mg/ml. The samples were separated on a Superdex S200 329 
10/300 (GE Healthcare) using 10 mM Tris pH 7, 250 mM NaCl as buffer.  Shimadzu LC Solutions 330 
software was used to control the HPLC and Astra V software for the HELEOS-II and rEX detectors.  331 
Data were analyzed using the Astra V software. MWs were estimated using the Zimm fit method with 332 
degree 1. A value of 0.174 was used for protein refractive index increment (dn/dc). 333 
 334 
 335 
 336 
 337 
Digestion of HEK293 cell extracts with OGA constructs 338 
HEK293 cells were obtained from ATCC. They were not further authenticated. However, as we are 339 
looking at total GlcNAc levels in cell extracts and the digestion of O-GlcNAc by OGA, rather than cell-340 
type specific physiology, the exact cell type is less relevant in our experiments. The cells were tested 341 
for mycoplasma contamination in June 2016 (negative result). HEK293 cells were cultured in high 342 
glucose (4.5 g/L) Dulbeccos Modified Eagle Medium (DMEM) supplemented with 10% (v/v) Fetal 343 
Bovine Serum (FBS), 100 units/mL Penicillin and 100 µg/mL Streptomycin in a 5% CO2 humidified 344 
incubator at 37 °C. Cells were seeded into a 100 mm cell culture dish and grown to 95% confluency. 345 
Cells were washed with ice-cold PBS, harvested by scraping on ice in ice-cold PBS, pooled and centri-346 
fuged at 700 g for 10 min at 4 °C. The cell pellet was resuspended in 150 µL of lysis buffer (50 mM 347 
NaH2PO4, pH 7.0, 100 mM NaCl, 1% (v/v) NP-40 substitute, 0.5% (w/v) sodium deoxycholate, and 1 348 
mM PMSF) and incubated on ice for 30 min. The cell extracts were then centrifuged at 14,000 g for 349 
10 min at 4 °C and the clear supernatant was collected. The protein concentration, determined by 350 
DC
TM protein assay (Bio-Rad), was 29 mg/mL. HEK293 cell lysates (5 µL, 150 µg) were mixed with 5 or 351 
25 µM of OGA-Split 1, OGA-L or BtGH84 (5.5 µL 2x solution in 50 mM NaH2PO4, 100 mM NaCl, pH 7.0) 352 
in the presence or absence of 250 µM Thiamet-G (0.6 µL 5 mM in PBS). The reactions were incubated 353 
at 25 °C for 3 hrs. Under these conditions, enzyme activity, as determined by pNP-GlcNAc hydrolysis, 354 
was shown to be stable (see Supplementary Figure 13). After the reaction, 4 µL of binding buffer (500 355 
mM NaH2PO4, 100 mM NaCl, pH 8.0) was added and the mixtures were added to 30 µL of Nickel-NTA 356 
Agarose beads (prewashed in binding buffer). The samples were incubated for 1 hr at rt with rotation 357 
to remove the His-tagged enzyme. The beads were spun down at 5,000 g for 2 min and the superna-358 
tant was collected (15 µL), mixed with 2x Laemmlis sample buffer containing ɴ-mercaptoethanol and 359 
boiled for 5 min at 100 °C. A third (~ 50 µg of protein) of each sample was resolved on a 4-20% Mini-360 
PROTEAN TGX gradient gel (Bio-Rad). The proteins were transferred onto a nitrocellulose membrane 361 
using a Bio-Rad wet western blotting system (1 hr at 100V). The membrane was blocked with 2% BSA 362 
in PBSt for 1 hr at rt and hybridized with mouse CTD110.6 antibody (BioLegend, 1:3,000) and rabbit 363 
anti-ɴ-actin antibody (LI-COR, 1:5,000) in PBS with 2% BSA overnight at 4 °C, followed by IRDye 680LT 364 
goat anti-mouse antibody (LI-COR, 1:10,000) and IRDye 800CW goat anti-rabbit antibody (LI-COR, 365 
1:10,000) in PBSt with 2% BSA for 1 hr at rt. Proteins were visualized using a LI-COR Odyssey scanner. 366 
The protein ladder used was a PageRuler Prestained Plus Protein Ladder (Thermo Fisher Scientific).  367 
 368 
Stability of OGA-Split 1 under reaction conditions 369 
The various OGA constructs were dissolved at 25 µM in 50 mM NaH2PO4, 100 mM NaCl, pH 7.0. The 370 
mixtures were incubated at 25 °C for 3 hrs. Before (t = 0 hrs) and after incubation (t = 3 hrs), 2 ali-371 
quots of 0.5 µL were taken out and each added to 125 µL of PBS. The diluted enzymes (100 nM) were 372 
then mixed 1:1 with of 400 µM 4-Nitrophenyl N-acetyl-D-glucosaminide (pNP-GlcNAc) in PBS and two 373 
45 µL aliquots (for duplicate reads) were transferred to a 384 well Corning clear-bottom plate. pNP-374 
GlcNAc hydrolysis was monitored continuously at a wavelength of 405 nm at 25°C using a Spectra-375 
Max i3x multi-mode plate reader (Molecular Devices). Background hydrolysis (the average value in 376 
samples without enzyme at the corresponding time point) was substracted from all values, after 377 
which reaction velocities were determined by linear regression of the progress curves. These values 378 
were then normalized to 100% activity (the average value in samples with the corresponding OGA 379 
construct at 0 hrs incubation). Data were analyzed using GraphPad Prism5 software and represent 380 
mean values ± standard deviation from two biological replicates with two technical replicates (dupli-381 
cate reads) each (Supplementary Fig. 16). 382 
 383 
 384 
Treatment of O-GlcNAcylated TAB1 with OGA constructs 385 
TAB1 was coexpressed with OGT in E.coli and purified as previously described.17 O-GlcNAcylated and 386 
HIS-tagged TAB1 (5 µg per sample, 2.5 µL 2 mg/mL in 50 mM NaH2PO4, 100 mM NaCl, pH 7.0) was 387 
treated with 5 or 25 µM of OGA-Split 1, OGA-L or BtGH84 (3 µL 2x solution in 50 mM NaH2PO4, 100 388 
mM NaCl, pH 7.0) in the presence or absence of 250 µM Thiamet-G (0.5 µL 3 mM in PBS) at 25 °C for 389 
3 hrs. The reactions were quenched by addition of 4 µL of 5x Laemmlis sample buffer containing ɴ-390 
mercaptoethanol and boiled for 5 min at 100 °C. A fifth (~ 1 µg of TAB1) of each sample was resolved 391 
on a 12% SDS-PAGE gel and analyzed by western blot as described above. Instead of rabbit anti-ɴ-392 
actin antibody, a rabbit anti-HIS antibody was used as loading control (Cedarlane, 1:5,000). 393 
Data Availability: 394 
The atomic coordinates and structure factors have been deposited in the Protein Data Bank under 395 
the accession codes 5M7R for the apo-structure, 5M7S for the Thiamet-G complex, 5M7T for the 396 
PugNAc-imidazole complex and 5M7U for the complex with VV347. Any other datasets generated 397 
during and/or analyzed during the current study are available from the corresponding author on 398 
reasonable request. 399 
 400 
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